![](/images/graphics-bg.png)
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
المؤلفون المشاركون
Faes, Seraina
Dormond, Olivier
Demartines, Nicolas
المصدر
Oxidative Medicine and Cellular Longevity
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-02-09
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Targeting mTORC1 has been thoroughly explored in cancer therapy.
Following encouraging preclinical studies, mTORC1 inhibitors however failed to provide substantial benefits in cancer patients.
Several resistance mechanisms have been identified including mutations of mTOR and activation of alternate proliferation pathways.
Moreover, emerging evidence discloses intratumoral heterogeneity of mTORC1 activity that further contributes to a reduced anticancer efficacy of mTORC1 inhibitors.
Genetic heterogeneity as well as heterogeneous conditions of the tumor environment such as hypoxia profoundly modifies mTORC1 activity in tumors and hence influences the response of tumors to mTORC1 inhibitors.
Intriguingly, the heterogeneity of mTORC1 activity also occurs towards its substrates at the single cell level, as mutually exclusive pattern of activation of mTORC1 downstream effectors has been reported in tumors.
After briefly describing mTORC1 biology and the use of mTORC1 inhibitors in patients, this review will give an overview on concepts of resistance to mTORC1 inhibition in cancer with a particular focus on intratumoral heterogeneity of mTORC1 activity.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Faes, Seraina& Demartines, Nicolas& Dormond, Olivier. 2017. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxidative Medicine and Cellular Longevity،Vol. 2017, no. 2017, pp.1-10.
https://search.emarefa.net/detail/BIM-1193928
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Faes, Seraina…[et al.]. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxidative Medicine and Cellular Longevity No. 2017 (2017), pp.1-10.
https://search.emarefa.net/detail/BIM-1193928
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Faes, Seraina& Demartines, Nicolas& Dormond, Olivier. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. Oxidative Medicine and Cellular Longevity. 2017. Vol. 2017, no. 2017, pp.1-10.
https://search.emarefa.net/detail/BIM-1193928
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1193928
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)